TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05584969

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer-led integrated nutrition education intervention delivered through Care Groups
Description: The intervention comprised a peer-led integrated nutrition education training using the Care Group model developed by the TOPS program \[13\]. In the treatment arms, topics trained in the peer support groups included 1) group dynamics and social support, 2) infant feeding 3) adequate basic hygiene, 4) child growth and development, and 5) fathers' involvement. The training modules were adopted and modified from the community health extension workers (CHEWs) handbook \[14\] and the UNICEF IYCF counseling cards for community workers \[15, 16\]. Over the study, the intervention participants also engaged in cooking demonstrations targeting infant complementary foods preparation and backyard kitchen gardening.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer-led integrated nutrition education intervention delivered through Care Groups
Description: The intervention comprised a peer-led integrated nutrition education training using the Care Group model developed by the TOPS program \[13\]. In the treatment arms, topics trained in the peer support groups included 1) group dynamics and social support, 2) infant feeding 3) adequate basic hygiene, 4) child growth and development, and 5) fathers' involvement. The training modules were adopted and modified from the community health extension workers (CHEWs) handbook \[14\] and the UNICEF IYCF counseling cards for community workers \[15, 16\]. Over the study, the intervention participants also engaged in cooking demonstrations targeting infant complementary foods preparation and backyard kitchen gardening.
Study: NCT04386707

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Three doses of experimental sIPV of lot 1 at the schedule of 2,3,4 months of age
Description: Three doses of experimental sIPV of lot 1 at the schedule of 2,3,4 months of age

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Three doses of experimental sIPV of lot 2 at the schedule of 2,3,4 months of age
Description: Three doses of experimental sIPV of lot 2 at the schedule of 2,3,4 months of age

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Three doses of experimental sIPV of lot 3 at the schedule of 2,3,4 months of age
Description: Three doses of experimental sIPV of lot 3 at the schedule of 2,3,4 months of age

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Three doses control wIPV at the schedule of 2,3,4 months of age
Description: Three doses control wIPV at the schedule of 2,3,4 months of age
Study: NCT01762033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASONEP
Description: Intravenous infusion
Study: NCT01852474

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: Subjects will receive tDCS stimulation 1x per day for 5 days (over the period of 1 week). Each session will be 20 minutes long. The subject will receive active stimulation for the entire 20 minutes.
Study: NCT01343485

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer reminder system
Description: Intervention sites will receive computer kiosk with study specific software to assist in reminding study participants to return for HPV vaccine series
Study: NCT01522105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daptomycin
Description: One dose of daptomycin given at an age appropriate dosage (3-24 months 6mg/kg; 2-6 years 10mg/kg; 7-11 years 8mg/kg; 12-16years 6mg/kg)
Study: NCT02446886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adrenocorticotropic hormone (ACTH) gel (H.P. Acthar®)
Description: Adrenocorticotropic hormone (ACTH) gel, a long-acting formulation of the full sequence ACTH that includes other pro-opiomelanocortin (POMC) peptides, is considered an alternative to corticosteroids in the treatment of relapses (currently FDA approved for this indication).~ACTH (H.P. Acthar®) gel exerts direct anti-inflammatory and immune-modulating effects within the CNS, specifically on infiltrating macrophages and resident microglia as well as protecting mature oligodendrocytes from inflammation-related damage and excitotoxicity. These effects are mediated not only via induction of endogenous corticosteroid production but also via effects on melanocortin receptors.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adrenocorticotropic hormone (ACTH) gel (H.P. Acthar®)
Description: Adrenocorticotropic hormone (ACTH) gel, a long-acting formulation of the full sequence ACTH that includes other pro-opiomelanocortin (POMC) peptides, is considered an alternative to corticosteroids in the treatment of relapses (currently FDA approved for this indication).~ACTH (H.P. Acthar®) gel exerts direct anti-inflammatory and immune-modulating effects within the CNS, specifically on infiltrating macrophages and resident microglia as well as protecting mature oligodendrocytes from inflammation-related damage and excitotoxicity. These effects are mediated not only via induction of endogenous corticosteroid production but also via effects on melanocortin receptors.
Study: NCT02373553

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EXERCISES
Description: The postural reeducation in a sitting position, in ventral and dorsal recumbency, including manual techniques, stretching the sternocleidomastoid and scalene muscles. Exercises for pelvic girdle positioning and stretching the hamstrings muscles tibial and sural triceps are associated with respiratory exercise. Twice a week during 3 months

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HEALTH EDUCATION
Description: Booklet contain many pictures demonstrating some exercises and an importance to do it.
Study: NCT02667717

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mirror therapy
Description: The intervention is a mirror therapy. The mirror therapy consists in performing some movements with a mirror, the hand that is painful is hidden and the image of the healthy hand is reflected in the mirror. Patients looking at this image seems to see their painful hand moving.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Patients will have the usual care as an intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Patients will have the usual care as an intervention.
Study: NCT03993912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab SC in combination with Lenalidomide
Description: Daratumumab SC 1800 mg~* once every week for 8 weeks~* then once every other week for 16 weeks~* thereafter once every 4 weeks, until progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide PO (25mg)
Description: Lenalidomide PO (25mg): days 1 through 21 of each 28-day cycle, until progression

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Lenalidomide PO (25mg)
Description: Lenalidomide PO (25mg): days 1 through 21 of each 28-day cycle, until progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone PO (20mg): days 1, 8, 15, 22 of each 28-day cycle, until progression
Description: Dexamethasone PO (20mg): days 1, 8, 15, 22 of each 28-day cycle, until progression

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Dexamethasone PO (20mg): days 1, 8, 15, 22 of each 28-day cycle, until progression
Description: Dexamethasone PO (20mg): days 1, 8, 15, 22 of each 28-day cycle, until progression
Study: NCT01354171

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI assisted TRUS guided biopsy
Description: All subjects to have a confirmatory biopsy at one year. Those assigned ARM 1 to have a TRUS guided biopsy and those assigned to ARM 2to have a MRI assisted TRUS guided biopsy
Study: NCT02917278

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Meals
Description: High Protein renal-specific meals
Study: NCT05467774

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Operant RF H-reflex conditioning
Description: Operant down-conditioning of rectus femoris H-reflex
Study: NCT01346436

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Minimally invasive rectopexy
Description: Use of a minimally invasive approach (robotic or laparoscopy) to perform a rectopexy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Minimally invasive rectopexy
Description: Use of a minimally invasive approach (robotic or laparoscopy) to perform a rectopexy
Study: NCT03448133

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magstim rTMS
Description: The device is made in London,UK

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Magstim rTMS
Description: The device is made in London,UK
Study: NCT01592864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stannous Fluoride
Description: dentifice

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Monofluorophosphate
Description: dentifrice
Study: NCT02660307

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PROGRESS group

Intervention type: OTHER
Group type: OTHER
Intervention: PROGRESS group
Study: NCT03353558

Intervention type: DEVICE
Intervention: Actigraph
Description: The watch will measure sleep parameters like quality of sleep, time to fall asleep, number of awakenings during night, length of deep sleep.

Intervention type: DEVICE
Intervention: Actigraph
Description: The watch will measure sleep parameters like quality of sleep, time to fall asleep, number of awakenings during night, length of deep sleep.
Study: NCT00506233

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Completion of questionnaires at 3 different times (when joining this study, 3 months later, and 6 months later). Each should take about 20-30 minutes to complete.
Study: NCT04053530

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: restorative materials
Description: glass ionomer and bulk fill flowable composite

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: restorative materials
Description: glass ionomer and bulk fill flowable composite

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: restorative materials
Description: glass ionomer and bulk fill flowable composite
Study: NCT04217122

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: strawberry powder
Description: Participants consume 2 packages of standard strawberry powder (13 g x 2) daily for 4 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo powder
Description: Participants consume 2 packages of placebo powder (13 g x 2) daily for 4 weeks
Study: NCT03442049

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy - Study group
Description: Study group : In addition to home program spinal stabilization exercises

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy - control group
Description: Home exercise program
Study: NCT04265560

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive Resistance Training
Description: Progressive resistance training programme for individuals following spinal cord injury.
Study: NCT00632398

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention control (reading)
Description: Caregivers read to the patient from literature of the patient's choice for recommended 20 minutes at least 3 times per week for 4 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Touch, Caring and Cancer DVD program
Description: DVD- and manual-based instruction for caregivers and patients in the use of touch and massage techniques as supportive care in cancer, including: preparation for a session, safety precautions related to cancer and its treatments, communication about touch, centering to calm the mind; manual techniques for the head, neck, shoulders, back, feet and hands to promote relaxation; and acupressure for pain, nausea and anxiety.
Study: NCT04536753

Intervention type: PROCEDURE
Intervention: Induction of labour
Description: Induction of labour using amniotomy, vaginal prostaglandin administration and syntocinon in combination as per protocol.

Intervention type: PROCEDURE
Intervention: Induction of labour
Description: Induction of labour using amniotomy, vaginal prostaglandin administration and syntocinon in combination as per protocol.

Intervention type: PROCEDURE
Intervention: Induction of labour
Description: Induction of labour using amniotomy, vaginal prostaglandin administration and syntocinon in combination as per protocol.
Study: NCT02963181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yohimbine
Description: Oral Yohimbine will be used to identify the integrity of post-ganglionic sympathetic nerves in patients with NOH

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Monitor the effects of melatonin on supine hypertension in NOH patients with intact and denervated post-ganglionic nerves.~Identify the mechanistic pathway of melatonin in blood pressure regulation
Study: NCT03438786

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trans-inguinal Pre-peritoneal Hernioplasty
Description: patients were catheterised pre-operatively, to prevent any injury to the bladder and aid in preperitoneal dissection. The catheter was removed after 48 hours post-operatively.~Incision of TIPP is same as that of Lichtenstein technique . After dissection of the sac, the transversalis is fascia is incised to enter the preperitoneal space. The preperitoneal space is developed by dissection with index finger. The space extends from rectus muscle medially, arcuate line cranially, a little beyond the anterior superior iliac spine over the psoas muscle laterally and the lilipubic tract caudally. A 15 cm x 15 cm polypropylene mesh, cut into dimension 15 cm x 12 cm, the inferior medial angle of the mesh is trimmed in a semicircular fashion to prevent trauma to the bladder neck. The mesh is placed in the preperitoneal space and anchored to the Cooper's ligament with a single 2-0 interrupted prolene suture

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lichtnestein's hernioplasty
Description: incision 1 cm above and parallel to inguinal ligament,Opening subcutaneous fat ,Opening Scarpa fascia to external oblique aponeurosis ,visualization of external ring and lower border of the inguinal ligament,Opening deep fascia of the thigh,checking for a femoral hernia ,Division of external oblique aponeurosis from external ring laterally for 5 cm, safeguarding ilioinguinal nerve ,Mobilization of superior and inferior flaps of external oblique aponeurosis exposing underlying structures ,Mobilization of spermatic cord along with the cremaster, including (ilioinguinal ,genitofemoral) nerves, and spermatic vessels; all of these structures may be encircled in a tape ,Opening of the coverings of spermatic cord, identification and isolation of the hernia sac ,Inversion, division, resection, or ligation of the sac ,Placement and fixation of mesh to edges of the defect or weakness in the posterior wall of inguinal canal creating artificial internal ring,Closure
Study: NCT02934321

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Erythritol
Description: Erythritol is a well tolerated, low calorie sugar alcohol that is becoming more widely used as a sugar substitute.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Aspartame
Description: Aspartame is a well tolerated, commonly used artificial sweetener.
Study: NCT03003559

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High flow nasal cannula
Description: High flow nasal cannula (HFNC) is a new emerging noninvasive respiratory support technology, which mainly includes high flow (15-60 L/min) device, heating humidification device and nasal cannula for high flow. A large number of physiological studies confirmed that HFNC has the following critical physiological effects: promoting airway humidification, improving tolerance of treatment, reducing the physiological dead space on the upper respiratory tract, producing a certain level of positive end expiratory pressure (2-7 cmH2O), decreasing the work of breathing and so on.
Study: NCT02852473

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure
Description: CPAP requires subjects to wear a plastic pressurized mask/apparatus, which is connected via a filter and hose to a pump capable of supplying variable pressure (typically on the range of 4-20 cm H2O). The investigators plan to use a full-face mask to prevent subjects from reducing pressure by opening their mouths. If this cannot be tolerated or properly fitted, or is not compatible with the CPAP ventilator, subjects would use a nasal mask only and be asked to keep their mouths closed.
Study: NCT00435890

Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Triage Liaison Physician
Description: triage liaison physician stationed with nurses at the triage desk of the Emergency Department.
Study: NCT02373254

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Ibuprofen 400 mg and 800 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Ibuprofen 400 mg and 800 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen/hydrocodone
Description: Norco 5/325 mg and 10/325 mg
Study: NCT04329832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Patients in the hydroxychloroquine arm will receive hydroxychloroquine 400 mg by mouth twice daily for 1 day, then 200 mg by mouth twice daily for 4 days (dose reductions for weight \< 45 kg or GFR (glomerular filtration rate)\<50ml/min). For patients \< 45kg, doses will be halved. For patients with GFR\<50ml/min, the final dose of hydroxychloroquine will not be administered. If the patient has already received hydroxychloroquine prior to randomization (no more than 2 days), the prior doses will count toward the 5-day total.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Patients in the azithromycin arm will receive azithromycin 500 mg on day 1 plus 250 mg daily on days 2-5 (may be administered intravenously per clinician preference). If the patient has already received azithromycin prior to randomization (no more than 2 days), the prior doses will count toward the 5-day total.
Study: NCT04508023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: Participants will receive rivaroxaban 10 mg tablet orally once daily.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching placebo tablet orally once daily.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care (SOC)
Description: SOC treatment will be determined by the investigator based on local practice and consists of supportive care.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care (SOC)
Description: SOC treatment will be determined by the investigator based on local practice and consists of supportive care.
Study: NCT03969147

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ManMaxAirway oropharyngeal airway adjunct
Description: Healthy volunteers will self-place the ManMaxAirway.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ManMaxAirway oropharyngeal airway adjunct
Description: Healthy volunteers will self-place the ManMaxAirway.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ManMaxAirway oropharyngeal airway adjunct
Description: Healthy volunteers will self-place the ManMaxAirway.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Guedel Oropharyngeal airway adjunct
Description: Healthy volunteers will self-place the standard Guedel OPA.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: No airway adjunct
Description: Healthy volunteers will have no airway adjunct in place.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: No airway adjunct
Description: Healthy volunteers will have no airway adjunct in place.
Study: NCT03598088

Intervention type: DEVICE
Group type: OTHER
Intervention: Ovaprene
Description: non-hormonal contraceptive ring
Study: NCT03343847

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Romiplostim
Description: This trial is designed to study romiplostim for the treatment of chemotherapy-induced thrombocytopenia (CIT) in patients receiving chemotherapy for the treatment of lymphoma.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator
Study: NCT04364009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra plus oSOC
Description: Anakinra plus Optimized Standard of Care (oSOC) on the condition of patients with COVID-19 infection and worsening respiratory symptoms.~The patients will receive intraveinous injection of Anakinra 400mg from Day 1 to Day 3 (two injections of 100 mg each 12 hours) and 200mg the remaining 7 days. The total duration of Anakinra is 10 Days. Efficient dosage of Anakinra as previously described will be continued until Day 10

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oSOC
Description: Optimized Standard of Care (oSOC) on the condition of patients with COVID-19 infection and worsening respiratory symptoms.
Study: NCT04603950

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CACB+IPACK
Description: continue adductor canal block plus Infiltration between the Popliteal Artery and Capsule of the Knee

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: CACB
Description: continue adductor canal block
Study: NCT01898923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ON101 Cream

Intervention type: OTHER
Group type: OTHER
Intervention: Aquacel® Hydrofiber® dressing